Evidence map›Paper›PMID 10049950›Full record

ArticleThe Journal of experimental medicine1999

Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation?

M Kerschensteiner, E Gallmeier, L Behrens, V V Leal, T Misgeld, W E Klinkert, R Kolbeck, E Hoppe, R L Oropeza-Wekerle, I Bartke and 4 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of experimental medicine, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 316 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
316citing papers in PubMed, 4 pooled it
14.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

316 citing papers in PubMed, 4 syntheses or guidelines pooled it, 1,019 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Nasal administration of anti-CD3 mAb (Foralumab) downregulatesProceedings of the National Academy of Sciences of the United States of America · 2023
    Trial
  7. Trial
  8. Efficacy and Safety ofNutrients · 2019
    Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review

256 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 2 countries.

M KerschensteinerDepartment of Neuroimmunology, Max Planck Institute for Neurobiology, D-82152 Martinsried, Germany.
E Gallmeier
L Behrens
V V Leal
T Misgeld
W E Klinkert
R Kolbeck
E Hoppe
R L Oropeza-Wekerle
I Bartke
C Stadelmann
H Lassmann
H Wekerle
R Hohlfeld
University of Vienna · ATLudwig-Maximilians-Universität München · DEBoehringer Ingelheim (Germany) · DEMax Planck Institute of Neurobiology · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Brain-derived neurotrophic factor (BDNF) has potent effects on neuronal survival and plasticity during development and after injury. In the nervous system, neurons are considered the major cellular source of BDNF. We demonstrate here that in addition, activated human T cells, B cells, and monocytes secrete bioactive BDNF in vitro. Notably, in T helper (Th)1- and Th2-type CD4(+) T cell lines specific for myelin autoantigens such as myelin basic protein or myelin oligodendrocyte glycoprotein, BDNF production is increased upon antigen stimulation. The BDNF secreted by immune cells is bioactive, as it supports neuronal survival in vitro. Using anti-BDNF monoclonal antibody and polyclonal antiserum, BDNF immunoreactivity is demonstrable in inflammatory infiltrates in the brain of patients with acute disseminated encephalitis and multiple sclerosis. The results raise the possibility that in the nervous system, inflammatory infiltrates have a neuroprotective effect, which may limit the success of nonselective immunotherapies.

Indexed as

AutoantigensB-LymphocytesBrain-Derived Neurotrophic FactorBrain DiseasesEncephalitisGlycoproteinsHumansInflammationLymphocyte ActivationMonocytesMultiple SclerosisMyelin Basic ProteinNeurodegenerative DiseasesOligodendrogliaRNA, MessengerT-LymphocytesAutoantigensBrain-Derived Neurotrophic FactorGlycoproteinsMyelin Basic ProteinRNA, Messenger

Identifiers

PMID10049950
PMCPMC2192942
OpenAlexW2120819751

What OpenQuestion holds

Texttitle and abstract
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.